Catalent Creates New Advanced Delivery Technologies Business Unit

Somerset, NJ – Catalent Pharma Solutions, a leading global drug development and advanced delivery technology company, today announced that it has created a new business unit, Advanced Delivery Technologies, which aligns the existing Modified Release and Medication Delivery businesses, including Catalent's growing Biologics technologies and capabilities. To address complex drug development challenges and provide broader customer solutions, the new unit will focus on innovative and proven drug delivery technologies, optimizing the company's multiple technologies, investment in capabilities, cross-platform R&D solutions and global commercial manufacturing network.

This structure will establish Catalent's Softgel Technologies, Advanced Delivery Technologies and Development & Clinical Services business units as global leaders in their respective markets.

Mr. Barry Littlejohns has been named President of the new business unit. Mr. Littlejohns has over 25 years of experience in the drug delivery industry spanning oral dose forms, parenteral delivery and biologics. He commented, "Our industry is facing tough challenges with increasingly difficult molecules, requiring more sophisticated development expertise, delivery technologies and supply capabilities to optimize bioavailability, therapeutic profiles and clinical outcomes. By bringing together talent and expertise from two proven teams, with our extensive intellectual property, technology and manufacturing platforms, we expect to partner with innovators around the world to deliver the most innovative, advanced and effective solutions to help bring more products to market faster and improve the efficacy of their treatments."

The new business unit will operate eight development and manufacturing facilities around the world including those for fast dissolve technologies at Swindon, UK; controlled release technologies in Winchester, KY, USA, which is currently undergoing a major expansion, the recently expanded Schorndorf, Germany site, and the advanced drug development center in Somerset, NJ, USA; the new Biologics center of excellence at Madison, WI, USA; advanced aseptic production in Woodstock, IL, USA; and pre-filled syringe facilities in Brussels, Belgium and Limoges, France.

To arrange an interview with Mr. Littlejohns, or other members of the leadership team, please contact Chris Halling at [email protected]

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.